Share this article
Share this article
HONG KONG, June 10, 2021 /PRNewswire/ CBMG Holdings (or the Company ), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced updated clinical data for C-CAR039, a novel CD19/CD20 bi-specific CAR-T cell product in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL). This work was presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, by the Principal Investigator (PI) of the study, Aibin Liang, M.D., Professor of Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine.
Additionally, the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted the Company an orphan drug designation (ODD) to C-CAR039, for the treatment of follicular lymphoma, an indolent form of Non-Hodgkin s Lymphoma.
Dalla medicina basata sulle evidenze a quella basata sulle eminenze Il caso AstraZeneca
quotidianosanita.it - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from quotidianosanita.it Daily Mail and Mail on Sunday newspapers.
Immutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast Cancer
marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.
Immutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast Cancer
First time an antigen presenting cell (APC) activator has shown an Overall Survival (OS) benefit in a randomised setting in metastatic breast cancer patients known to be insensitive to immune checkpoint inhibitor therapy
Promising and improving overall trend in OS in total population (based on approx. 60% of events): median survival benefit of +2.7 months from efti plus chemotherapy, compared to chemotherapy plus placebo
Statistically significant OS benefit in efti group observed in pre-defined patient groups:
+7.1 months survival benefit (median of 21.9 vs. 14.8 months, nearly 50% longer) from efti with chemotherapy for patients under 65 years of age